We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current REPL market cap is 402.7M. The company's latest EPS is USD -2.8391 and P/E is -2.31.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -41.58M | -41.63M | -53M | -55.65M | -63.83M |
| Net Income | -43.1M | -39.69M | -49.24M | -49.56M | -60.04M |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -30.95M | -56.2M | -79.96M | -118.31M | -177.08M |
| Net Income | -30.83M | -52.63M | -80.87M | -118.04M | -174.28M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 436.1M | 678.55M | 646.59M | 603.89M | 562.4M |
| Total Liabilities | 52.02M | 83.21M | 91.3M | 89.86M | 97.23M |
| Total Equity | 384.07M | 595.35M | 555.29M | 514.03M | 465.17M |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 154.33M | 234.1M | 543.1M | 461.19M | 646.59M |
| Total Liabilities | 16.47M | 50.38M | 44.37M | 49.96M | 91.3M |
| Total Equity | 137.86M | 183.72M | 498.73M | 411.23M | 555.29M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -66.67M | -95.25M | -128.05M | -48.59M | -92.18M |
| Investing | 5.35M | -119.75M | -142.5M | 7.36M | 20.04M |
| Financing | 39.95M | 311.38M | 311.3M | 1.11M | 1.54M |
| Year End March 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -25.38M | -60.55M | -61.39M | -82.18M | -128.05M |
| Investing | -65.94M | -5.23M | -188.78M | -1.81M | -142.5M |
| Financing | 101.39M | 100.17M | 372.46M | 6.6M | 311.3M |
| Market Cap | 402.7M |
| Price to Earnings Ratio | -2.31 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 2.75 |
| Price to Book Ratio | 0.73 |
| Dividend Yield | - |
| Shares Outstanding | 61.39M |
| Average Volume (1 week) | 706.79k |
| Average Volume (1 Month) | 794.65k |
| 52 Week Change | -62.23% |
| 52 Week High | 24.81 |
| 52 Week Low | 5.25 |
| Spread (Intraday) | 0.63 (9.37%) |
| Company Name | Replimune Group Inc |
| Address |
corporation trust center wilmington, delaware 19801 |
| Website | https://www.replimune.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
